Bruna Pellini, Chief of Thoracic Oncology at Miami Cancer Institute and Associate Professor at Florida International University – Herbert Wertheim College of Medicine, shared a post on LinkedIn:
“Our new manuscript in Translational Lung Cancer Research examines a combination strategy for KRASG12C-mutant NSCLC: sotorasib plus trastuzumab deruxtecan.
In preclinical models, this combination produced deeper and more durable tumor regressions than either treatment alone, including in models that had relapsed on sotorasib. That finding felt especially important because resistance remains one of the central challenges in this disease setting. It is often in those moments, when a treatment stops working and choices become more limited, that the translational questions feel most urgent.
We also explored HER2 expression in patient tumors and found a more complicated picture. HER2 was present in a subset of samples, but interpretation varied depending on the scoring system used. For me, that is one of the most important parts of this work. A promising treatment strategy is only part of the equation. We also need better tools to understand who may benefit and how to evaluate those tumors in a way that is meaningful in lung cancer.
This project was shaped by a truly collaborative effort and a strong sense of shared purpose. A special thanks to my stellar colleagues that co-lead this work with me Hilal Ozakinci, Bina Desai, Andriy Marusyk, my dear mentor Eric Haura and all of our other collaborators: Humberto Trejo Bittar, Theresa Boyle, Gina Nazario, Hitendra Solanki.
This work helped support the development of my first investigator-initiated clinical trial evaluating this combination in patients with KRAS G12C-mutant NSCLC (NCT07012031).”
Title: Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C-mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors
Authors: Hilal Ozakinci, Bina Desai, Denise Kalos, Dung-Tsa Chen, Menkara Henry, Hitendra Solanki, Theresa A. Boyle, Humberto E. Trejo Bittar, Gina S. Nazario, Eric B. Haura, Andriy Marusyk, Bruna Pellini
Read the Full Article.
T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC
